1 June 2015 in The American Journal of Cardiology
1 February 2015 in International Journal of Cardiology
19 November 2018 in Herzschrittmachertherapie + Elektrophysiologie
Konventionelle Herzschrittmachersysteme mit Generatoren unter dem Schlüsselbein und zum Herzen führenden Elektroden haben seit mehr als 60 Jahren das Leben von Millionen Menschen verbessert oder verlängert. Dennoch weisen sie Schwachstellen auf, die zu Fehlfunktionen oder Infektionen mit bedrohlichen Folgen führen können. Sondenlose Herzschrittmacher („leadless pacemakers“) wurden während der letzten Jahre entwickelt und in die klinische Praxis eingeführt. Sie sollen helfen, die Probleme konventioneller Schrittmacher zu überwinden. Anhand des derzeit einzigen kommerziell erhältlichen sondenlosen Schrittmachers, Micra™ (Medtronic Inc., Minneapolis, MN, USA), sollen die klinischen Erfahrungen und weiteren Perspektiven dieser vielversprechenden Technologie beleuchtet werden. Leadless pacemakers have the potential to fundamentally change the field of device therapy. As leads and generator pockets are no longer needed with this technology, many potentially dangerous complications of conventional pacemaker systems like lead fractures, lead endocarditis or pocket infections can be effectively avoided. At present, Micra™ (Medtronic Inc., Minneapolis, MN, USA) is the only commercially available leadless pacemaker. Since its first-in-human implantation in 2013, thousands of these devices have been implanted worldwide. This article presents an overview of the present clinical evidence and future perspectives of this promising new technology.
29 May 2015 in Catheterization and Cardiovascular Interventions
1 January 2015 in International Heart Journal
Acute graft rejection in patients after heart transplantation can cause arrhythmias and acute angina pectoris with electrocardiographic ST-segment elevation. We report a case of a 53-year old female patient who had undergone cardiac transplantation 8 years previously. She developed bradycardia with co-existent ST-segment elevation caused by a histologically proven acute graft rejection. After administration of methylprednisolone and immune absorption leading to initial clinical improvement, the patient died unexpectedly. The reasons remain unclear, but a degeneration of the conduction system as well as impaired blood flow in the right coronary caused by cellular and humoral rejection most likely have both contributed.